Core Viewpoint - Hualan Co., Ltd. has repurchased a total of 2.9757 million shares, representing 1.81% of the company's total share capital, with a total expenditure of approximately 99.9795 million yuan as of October 31, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through a dedicated securities account via centralized bidding [1] - The highest transaction price was 34.800 yuan per share, while the lowest was 28.700 yuan per share [1] - The total amount of funds used for the repurchase, excluding transaction fees, was 99.9795 million yuan [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-110 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Core Viewpoint - Hualan Co., Ltd. is a significant player in the domestic market for injectable drug packaging materials, with strengths in technology research and product quality [1] Group 1: Business Performance - In Q3 2025, Hualan's revenue reached 441 million yuan, ranking 34th in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The main business composition includes film-coated rubber stoppers at 152 million yuan (49.07%) and conventional rubber stoppers at 150 million yuan (48.50%) [2] - The net profit for the same period was 53.23 million yuan, also ranking 34th in the industry, with the industry leader, Lepu Medical, achieving 999.6 million yuan [2] Group 2: Financial Ratios - Hualan's debt-to-asset ratio was 13.48% in Q3 2025, up from 9.77% year-on-year, which is lower than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 38.92%, slightly down from 39.15% year-on-year, and below the industry average of 48.78% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.09% to 13,300, while the average number of circulating A-shares held per shareholder increased by 49.59% to 11,800 [5] - Hualan's main business is expected to grow steadily, with projected revenue growth of 15-20% in 2025 due to increased demand from pharmaceutical clients and high-end orders [5] Group 4: Management and Compensation - The chairman, Hua Yimin, received a salary of 1.03 million yuan in 2024, unchanged from 2023 [4]

Core Points - Hualan Co., Ltd. announced the completion of its employee stock ownership plan, with 2.87437 million shares transferred to the plan's account at a price of 19.47 yuan per share [1] - The remaining 45,630 shares will be reserved for future grants, with specific details to be determined within 12 months after shareholder approval [1]

江苏华兰药用新材料股份有限公司 关于 2025 年员工持股计划首次授予非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301093 证券简称：华兰股份 公告编号：2025-109 江苏华兰药用新材料股份有限公司（以下简称"公司"或"华兰股份"）于 2025 年 9 月 19 日召开第六届董事会第五次会议，并于 2025 年 10 月 9 日召开公 司 2025 年第五次临时股东会，审议通过了《关于公司＜2025 年员工持股计划 （草案）＞及其摘要的议案》《关于公司＜2025 年员工持股计划管理办法＞的 议案》《关于提请股东会授权董事会办理 2025 年员工持股计划相关事宜的议案》。 股东会同意公司实施 2025 年员工持股计划（以下简称"本员工持股计划"），并 授权董事会办理与本员工持股计划相关的事宜。具体内容详见公司在巨潮资讯 网（www.cninfo.com.cn）披露的相关公告。 根据《中华人民共和国公司法》《中华人民共和国证券法》《关于上市公司 实施员工持股计划试点的指导意见》《深圳证券交易所上市公司自律监管指引第 2 ...

江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第 二十七次会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置 募集资金和自有资金进行现金管理的议案》，同意公司及子公司使用不超过人民 币 130,000 万元的闲置募集资金（含超募资金，下同）和自有资金进行现金管理， 其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效 期为公司股东大会审议通过之日起 12 个月内，上述额度在有效期内可循环滚动 使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯 网（www.cninfo.com.cn）上披露的《关于使用部分闲置募集资金和自有资金进行 现金管理的公告》（公告编号：2024-111）。 一、本次使用部分闲置募集资金进行现金管理到期赎回情况如下： 金额单位：万元 | 序 号 | 受托方 | | 产品名称 | | 产品 类型 | 金额 | 收益 起算日 | 产品 到期日 | 资金 来源 | 产品 收益 | | -- ...

Core Viewpoint - Jiangsu Hualan Pharmaceutical Materials Co., Ltd. plans to establish a wholly-owned subsidiary in Hainan Province with an investment of 50 million RMB, focusing on pharmaceutical production and technology research [2] Company Overview - Hualan Co. was established on June 4, 1992, with a registered capital of 1,642.01624 million RMB, and is primarily engaged in the R&D, production, and sales of packaging materials for injectable drugs [2] - The company has four subsidiaries, including Chongqing Fuling Sanhai Lanling Co., Ltd. and Jiangsu Hualan Dangseng Biotechnology Co., Ltd. [2] Financial Performance - The company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 were 584 million RMB, 623 million RMB, 586 million RMB, and 441 million RMB, reflecting year-on-year changes of -28.84%, 6.64%, -5.86%, and 4.36% respectively [3] - The net profit attributable to the parent company for the same periods was 93.75 million RMB, 118 million RMB, 49.57 million RMB, and 53.32 million RMB, with year-on-year growth rates of -56.60%, 25.79%, -57.96%, and 2.06% respectively [3] - The company's asset-liability ratios for the same periods were 6.36%, 8.31%, 10.22%, and 13.48% [3]

Group 1 - Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd. has been established with a registered capital of 50 million yuan [1] - The company's business scope includes artificial intelligence industry application system integration services, AI application software development, AI public data platform, and AI basic software development [1] - The company is wholly owned by Hualan Biological Engineering Inc. (stock code: 301093) [1]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has shown a significant increase in stock price and trading volume, indicating investor interest and activity in the company [1][2] - On October 24, Hualan's stock price rose by 2.48%, with a trading volume of 121 million yuan, and the company experienced a net financing outflow of 340.99 million yuan [1] - As of October 24, the total margin balance for Hualan was 494 million yuan, accounting for 7.60% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, Hualan had 13,300 shareholders, a decrease of 13.09% from the previous period, while the average circulating shares per person increased by 49.59% to 11,820 shares [2] - For the period from January to September 2025, Hualan reported a revenue of 441 million yuan, representing a year-on-year growth of 4.36%, and a net profit attributable to shareholders of 53.32 million yuan, up 2.06% year-on-year [2] - Since its A-share listing, Hualan has distributed a total of 238 million yuan in dividends, with 144 million yuan distributed over the past three years [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 本次投资概述 证券代码：301093 证券简称：华兰股份 公告编号：2025-107 江苏华兰药用新材料股份有限公司 关于投资设立全资子公司的进展公告 四、 备查文件 （一）《海南灵擎数智医药科技有限公司营业执照》 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2025 年 09 月 26 日召开第六届董事会第六次会议，审议通过了《关于公司投资 设立全资子公司的议案》。根据公司战略布局和产业发展的需要，公司拟使用自 有资金人民币 5,000 万元在海南省投资设立全资子公司，具体内容详见公司 2025 年 09 月 26 日披露于巨潮资讯网（www.cninfo.com.cn）上的《关于公司投 资设立全资子公司的公告》（公告编号：2025-099）。 （二）深交所要求的其他文件 二、 本次投资进展情况 特此公告。 近日，全资子公司已完成工商注册登记手续，并取得海南省市场监督管理 局颁发的《营业执照》，具体信息如下： | 名称 | 海南灵擎数智医药科技有限公司 | | | | | --- ...